CME in Minutes: Education in Oncology & Hematology podcast

What's CME in Minutes: Education in Oncology & Hematology about?

Get answers in 25 minutes or less from world-class experts and earn CME/CE credit with CME in Minutes: Education in Oncology & Hematology by Answers in CME. Benefit from digests of latest advancements, thoughtful case studies, and nuanced perspectives anytime, anywhere, and on any device. Inspiring and engaging programs designed for oncologists and hematologists to cover the diagnosis, staging, treatment, follow-up, and clinical management of tumors and hematological malignancies. Earning your CME/CE credits has never been faster or easier. Visit the URL for each individual program to request continuing education credit or access the slides.

What's CME in Minutes: Education in Oncology & Hematology about?

Download our free app to listen on your phone

CME in Minutes: Education in Oncology & Hematology episodes:

Ben Carpenter, MD, PhD - Exploring Novel Therapeutic Frontiers in Transfusion-Dependent Beta Thalassemia: The Path to Transfusion Independence

Saad Z. Usmani, MD, MBA, FACP, FASCO - Making the Case for Triple Therapy in R/R Multiple Myeloma: Expert Guidance for Optimizing Anti-CD38 mAb Regimens

Josep M. Llovet, MD, PhD - Redefining How to Treat Intermediate-Stage HCC: Exploring TACE Plus Immunotherapy–Based Combination Therapy

Richard Kim, MD - Enhancing Treatment Sequencing to Extend Survival: Tailoring Later-Line Care to the Patient With Metastatic Colorectal Cancer

Jyoti Mayadev, MD - From Routine Screening to Applying Clinical Advances in Locally Advanced Cervical Cancer: Evolving Care in High-Risk Populations

Geoffrey Ku, MD, MBA - Conversations in Precision Oncology: Harnessing Testing to Drive Personalized Treatment in HER2-Positive Advanced Gastric Cancer

Peter Lio, MD - Generative AI: Benefits for Your Practice, for Your Patients

Peter Lio, MD - AI in Healthcare: A Primer for the Practicing Clinician

Aditya Bardia, MD - Endocrine Sensitivity in the Real World: Practical Guidance to Optimize Second-Line Care in ER-Positive, HER2-Negative Advanced Breast Cancer

Martin C. Mahoney, MD, PhD - Reducing the Burden of HPV-Related Cancers: Strategies for Improving HPV Vaccine Uptake in Males

Laura Spring, MD - The Patient-Clinician Alliance to Enhance Care for Patients With Metastatic Breast Cancer on Antibody-Drug Conjugates

Heather Wakelee, MD - Stepping Up Clinical Outcomes for Resectable NSCLC: Examining the Role of Neoadjuvant Plus Adjuvant Immunotherapy Regimens

Sue S. Yom, MD, PhD - Latest Updates in Locally Advanced Squamous Cell Carcinoma of the Head and Neck: The Clinical Potential of Inhibitor of Apoptosis Protein (IAP) Antagonists to Change the Treatmen

Steven M. Horwitz, MD - Advancing The Treatment Paradigm in Relapsed/Refractory B- and T-Cell Lymphoma: The Evolving Role of EZH1/2 Pathway Inhibitors

Stephen M. Ansell, MD, PhD / Caron Jacobson, MD, MMSc - Navigating a New Treatment Algorithm for Patients With Relapsed/Refractory Follicular Lymphoma: Where Do CD20 x CD3 Bispecific Antibodies Fit In

Nikhil I. Khushalani, MD - Pointing the Way to Enhanced Outcomes in Resectable Cutaneous Squamous Cell Carcinoma: Practical Strategies to Incorporate Neoadjuvant Immunotherapy

Susana M. Campos, MD, MPH - Expanding the Potential of HER2-Directed Antibody-Drug Conjugates: Evidence and Application in New Tumor Types

Evan J. Lipson, MD - Real Talk About Maximizing Care in Advanced Melanoma: Balancing Benefit and Risk Using Dual Immunotherapy Regimens

John N. Allan, MD - Enhancing Patient Outcomes in Relapsed/Refractory Follicular Lymphoma: Recognizing the Role of Novel Bispecific Antibody–Based Therapies

Peter R. Galle, MD, PhD - Assembling a Long-Term Sequential Plan for Unresectable HCC: Practical Guidance for Improving Real-World Outcomes

Tanya Siddiqi, MD - Addressing Patient Needs With CAR T-Cell Therapy in the Treatment of CLL/SLL: Preparing for an Evolving Treatment Paradigm

David M. Miller, MD, PhD / Kevin Emerick, MD - Coming Together to Improve Outcomes in Resectable Cutaneous Squamous Cell Carcinoma: Multidisciplinary Care Strategies With Neoadjuvant Immunotherapy

Manish A. Shah, MD - Keeping Current on Frontline Immunotherapy-Chemotherapy Combinations: HER2-Positive and HER2-Negative Unresectable Advanced Gastric or GEJ Adenocarcinoma

Adam Brufsky, MD, PhD - Getting Real With Patients During Clinical Decision-Making: The Value of Sharing Real-World Evidence About CDK4/6 Inhibitors for HR+/HER2- Metastatic Breast Cancer

Patrick Forde, MB, BCh - Keeping the Dialogue Open in Early-Stage NSCLC: Instituting a Multidisciplinary Approach

Vishal A. Patel, MD - Making Headway in Treating Resectable Cutaneous Squamous Cell Carcinoma: Setting Sights on Neoadjuvant Immunotherapy

Josep M. Llovet, MD, PhD - Enhancing Long-Term Survival in Unresectable HCC: Optimizing First-Line Immunotherapy-Based Combination Regimens

Wolfgang Miesbach, MD, PhD - Gene Therapy in Hemophilia A: Redefining the Treatment Paradigm

Jorge Cortes, MD - Third-Line Therapies in Chronic Myeloid Leukemia: Evolving to Overcome the Limitations of Early-Generation Tyrosine Kinase Inhibitors

Asa Radix, MD, PhD, MPH - A Call to Action to Prevent Cervical Cancer in Transgender and Nonbinary Populations: Patient-Centered Strategies to Increase Screening Rates

Trisha Wise-Draper, MD, PhD - Empowering Precision Decisions: PD-1 Inhibitor-Based Therapies and Biomarker Testing in R/M HNSCC

Richard Finn, MD - Improving Patient Outcomes in Advanced Biliary Tract Cancer: Evaluating the Promise of Immunotherapy Plus Chemotherapy Combinatorial Approaches

Matthew R. Smith, MD, PhD - Combined Systemic Therapy to Combat Metastatic Hormone-Sensitive Prostate Cancer

Joshua Richter, MD / Saad Z. Usmani, MD, MBA, FACP - Optimizing Patient Outcomes in Relapsed/Refractory Multiple Myeloma: The Role of Novel BCMA-Targeted Bispecific Antibodies

Sapna P. Patel, MD - Enhancing Neoadjuvant and Adjuvant Treatment in Resectable Melanoma: Is Timing the Key to Improved Outcomes?

Alexander I. Spira, MD, PhD, FACP - Breaking News in NSCLC: The Latest Evidence on Emerging Antibody Drug Conjugates Targeting TROP2

Eric K. Singhi, MD / Charu Aggarwal, MD, MPH - It Takes Two to Tango: Exploring the Clinical Implications of First-Line Immunotherapy Plus Chemotherapy Combinations in Advanced NSCLC

Jamie E. Chaft, MD - Enhancing Outcomes for Patients With Resected, Early-Stage NSCLC: A Piercing Evaluation of the Clinical Support for Adjuvant Immunotherapies

Stephen Lam Chan, MD - Recalibrating Survival: Available and Recently Approved Immunotherapy-Based Combination Approaches in Unresectable HCC

Eric Jonasch, MD - Optimizing Long-Term Care With Guideline-Recommended Systemic Treatment Options for von Hippel-Lindau Disease-Associated Renal Cell Carcinoma

Enriqueta Felip, MD, PhD / David Harpole, MD - Reflecting on the Role of Perioperative Immunotherapeutic Regimens for Resectable Non–Small-Cell Lung Cancer: Evaluating the Evidence to Determine Better

Saad Z. Usmani, MD, MBA, FACP / Gareth J. Morgan, MD, PhD - Strength in Numbers: Triplet Combination Therapies in Relapsed/Refractory Multiple Myeloma (RRMM) Special Patient Populations

Miguel-Angel Perales, MD - Shifting Gears in Treating Relapsed and Refractory Indolent B-Cell Lymphomas: Where Do CAR T Cell Therapies Stand in FL and CLL/SLL?

Ticiana Leal, MD - Inspiring Improved Outcomes in Advanced NSCLC: A Patient-Centered Approach to Integrating Combination Locoregional and Immunotherapy Into Care

Tanios Bekaii-Saab, MD / Kelley A. Rone, DNP, AGNP-c - Providing Holistic Care for Hand-Foot Skin Reaction to Improve Outcomes for Patients on Multikinase Inhibitor Therapy for CRC

Sara A. Hurvitz, MD, FACP / Miguel Martín, MD, PhD - Integrating Advances in HR+ HER2- Early Breast Cancer: A Focus on Targeted Adjuvant Regimens

Axel Hauschild, MD - Advancing Outcomes in Surgically Resectable Cutaneous Squamous Cell Carcinoma: Carving New Paths Forward With Immunotherapies

Javier Cortés, MD / Sarah Donahue, MPH, ANP, AOCNP - Putting Patients First: Optimizing Outcomes via Collaborative Care in Pretreated Advanced Triple Negative Breast Cancer Treatment

Dirk Schadendorf, MD - An Evolution in Care for Advanced Melanoma: Exploring the Clinical Implications of Approved and Emerging Anti–LAG-3/PD-1 Combinations

Jonathan Schoenfeld, MD, MPH - Evolving the Treatment Landscape in Head and Neck Squamous Cell Carcinoma: Promoting Apoptosis With Emerging Antagonists of Inhibitors of Apoptosis Proteins

Other shows like CME in Minutes: Education in Oncology & Hematology: